A phase II clinical trial evaluating adoptive cell therapy with autologous tumor infiltrating lymphocytes infusion followed by IL-2 for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck is currently active (NCT03083873). The gene discussed is IL2; the disease is metastatic squamous cell carcinoma.